

## Antitumor Effects of Umbelliprenin in a Mouse Model of Colorectal Cancer

Mohamad Naderi Alizadeh<sup>a</sup>, Mohsen Rashidi<sup>b, c</sup>, Ahad Muhammadnejad<sup>d</sup>, Taraneh Moeini Zanjani<sup>a</sup> and Seyed Ali Ziaei<sup>a\*</sup>

<sup>a</sup>Department of Pharmacology, school of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. <sup>b</sup>Department of Physiology and Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. <sup>c</sup>The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran. <sup>d</sup>Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.

### Abstract

Umbelliprenin is a sesquiterpene coumarin with *in vitro* anti-carcinogenic activities. The aim of this study was to investigate the antitumor effects of umbelliprenin in animal models of colorectal cancer. The cytotoxic effects of umbelliprenin were explored on CT26 and L929 by MTT assay. In this study, colorectal tumors developed in mice by intradermal injection of CT26 cell line. Tumor size, serum levels of IFN- $\gamma$  and IL-4 by ELISA, and Ki-67, MMP2, MMP9, VEGF and E-cadherin markers by IHC method were evaluated. The results showed that umbelliprenin inhibited the cancer cells in a concentration-dependent manner. IC50 Evaluation showed that L929 cells were more resistant to Umbelliprenin than CT26 cells. Umbelliprenin treatment in both tumor-bearing mice and control normal mice showed significantly increased IFN- $\gamma$  and decreased IL-4 ( $P < 0.05$ ). The pathologic findings had shown that the E-cadherin marker in the umbelliprenin treated cancerous mice were significantly higher compared to the control group ( $P < 0.05$ ) while the expression of Ki-67 marker was reduced significantly ( $P < 0.05$ ). Markers involved in angiogenesis including VEGF, MMP2, and MMP-9 in the cancerous mice group treated with umbelliprenin showed a significant decrease compared to the control group ( $P < 0.05$ ). Metastasis to lung and liver was reduced in umbelliprenin treated group. Our results showed that umbelliprenin inhibited CT26 tumor cells *in-vitro*. The *in-vivo* reduction of tumor size, angiogenesis, and proliferation markers and the absence of metastasis represents the antitumor effects of umbelliprenin on colorectal cancer. The results showed that umbelliprenin can be considered as a good candidate for the treatment of colorectal cancer.

**Keywords:** Umbelliprenin; Colorectal cancer; cytotoxic effect; Anti-carcinogenic effect; Immunohistochemistry; CT26, Anti-angiogenesis.

### Introduction

Colorectal cancer is the second reason of

mortality in USA and also the third causing agent of mortalities related to cancer in Iran (1, 2). Umbelliprenin is considered as an anti-cancer agent with cytotoxic effects (3). Umbelliprenin is a sesquiterpene coumarin that is synthesized by different spices of *Ferula* of

\* Corresponding author:  
E-mail: saziai@gmail.com

umbeliferace (4). Various studies have shown that umbelliprenin possess different biologic and pharmacologic characteristics such as anti-inflammatory, antioxidant, cytotoxic, antibacterial, antimalarial, anti-HIV, anti-leishmania, antihypertensive, anti-osteoporosis, and antiarrhythmic (5-8). Results of the new researches have shown that umbelliprenin causes inhibition of specific matrix metalloprotease and oxidosqualene cyclase activity and also has pro-apoptotic characteristics and anti-cancer effects (6, 9). This compound increases lymphocytes response to mitogens and induces immune system-related anti-tumor effects. Furthermore, possibly because of intervention with fibrinolytic system, umbelliprenin can affect angiogenesis and it decreases metastasis (3, 10). This study was designed to evaluate anti-tumor effects of umbelliprenin on an animal model of colorectal cancer.

## Experimental

### MTT assay

The CT26 and L929 cell lines (cell lines were purchased from Pasteur institute) were cultured in RPMI-1640 (Gibco®, Life Technologies, USA) medium supplemented with 10% fetal bovine serum (Gibco®, Life Technologies, USA), and 1% penicillin/streptomycin (100 U/mL) in a humidified atmosphere containing 5% CO<sub>2</sub> and 95% air at 37 °C. The cells were seeded into 96-well culture plates at densities of  $1 \times 10^5$  cells per well. After 24 h, they were treated with 3, 6.25, 12.5, 25, 50, 100 and 200 µg/mL umbelliprenin for 24, 48 and 72 h. After the treatment time passed, 10 µL of MTT solution was added to each well of 96-well plates and incubated for 4 h at 38 °C, then the purple MTT-formazan crystals were dissolved by adding 150 µL of DMSO. The absorbance of the samples were measured with ELISA reader at 540 nm.

### Colorectal cancer model and study groups

Six to eight-weeks age BALB/c mice (Pasteur institute, Tehran, Iran) were divided into two main groups including tumor groups and non-tumor control groups. In tumor groups, CT26 cancer cells were injected subcutaneously ( $1 \times 10^5$  cells/0.1 mL PBS/mouse) into the lower

right flanks of each mice. After 17 days, when the tumors had reached an average volume of 400–500 mm<sup>3</sup>, the tumor-bearing BALB/c mice were intraperitoneally injected with umbelliprenin (pharmaceutical grade synthesized by research center of Mashhad University of Medical Sciences, Iran) 12.5 mg/kg/ 200µL liquid paraffin (group A, n = 6), liquid paraffin 200µL (group B, n = 6), and normal saline 200µL (group C, n = 6) daily for one week. Similar protocol was carried out on control mice with the injection of Umbelliprenin with liquid paraffin (group D, n = 6), liquid paraffin (group E, n = 6), and normal saline (group F, n = 6). This study was approved by Shahid Beheshti University of Medical Sciences Research Ethical Committee (IR. SBUM.RETECH.REC.1395.847).


### Tumor Volume calculation

According to Khaghanzadeh *et al.*(11), tumor volume (mm<sup>3</sup>) was determined in tumor-bearing animals, on a 2-day intervals schedule, with a digital caliper in 12 to 34<sup>th</sup> days after the injection. Tumor volume based on caliper measurements were calculated by Jensen *et al.* study formula (12):

$$\text{Tumor volume} = 1/2(\text{length} \times \text{width}^2)$$

### Histopathological assay

All mice, after anesthesia by co<sub>2</sub>, were sacrificed with cervical dislocation. Tissue samples as well as Liver, lung, and kidneys were collected from all animals, fixed in formalin and embedded in paraffin. Then, 5-µm cuts were prepared from each tissue block and were subjected to routine Hematoxylin and Eosin (H&E) staining. The stained slides were examined by light microscopy. Pathologic complete response (pCR) assessment was assumed, which measures response to dealing based on the amount of remaining tumor cells, as well as mitosis, necrosis, and pleomorphic rate. The pCR scoring follows as; R = 0, there is no response and no evidence regarding the reduced population of the malignant cells; R = 1, there is a partial-weak response and at least 30% of malignant cell fibrosis is observed; R = 2, there is a partial-moderate response and at least 70% of malignant cell fibrosis is observed; R = 3,



**Figure 1.** The survival rate of L929 and CT26 after treatment with umbelliprenin in 24, 48 and 72 h incubation times.

there is a complete response and no presence of the malignant cells.

#### *Immunohistochemistry assay*

Formalin-fixed and paraffin-embedded tissue slides were also subjected to immunohistochemical assay of Ki-67(ab15580 Abcam, USA), CD31 (ab28364 Abcam, USA), VEGF (ab46154 Abcam, USA), MMP2 (ab37150 Abcam, USA), MMP9 (ab38898 Abcam, USA), and E-Cadherin (PM 170 AA Biocare, UK) using commercially available antibodies according to the manufacturers' instructions, and being analyzed by an expert pathologist. Rate staining as (0) - no stained cells, (1) - stained cells <1/100, (2) - 1/100 ≤ stained cells < 1/10, (3) - 1/10 ≤ stained cells < 1/3, (4) - stained cells = 1/3 & < 2/3, (5) - stained cells > 2/3; Intensity as 0 = none, 1 = weak, 2 = intermediate, 3 = strong; and Allred score as 0–1 = no reactive, 2–3 = weak reactive, 4–6 = intermediate reactive, 7–8 = high reactive

#### *Determination of IFN-γ and IL-4*

Serum concentrations of IFN-γ (HRP, MABTECH, Sweden) and IL-4 were measured by enzyme-linked immunosorbent assay (ELISA) using specific kits (HRP, MABTECH, Sweden) according to the manufacturer's guidelines. The o-phenylenediamine was used as chromogenic substrate for the horseradish peroxidase enzyme. The color intensity produced because of oxidative coupling reaction

of the substrate and enzyme and was assessed at a wavelength of 492 nm, using an Anthos 2020 micro plate reader (Anthos, Wals, Austria).

#### *Data analysis*

The data were analyzed using the GraphPad Prism 4 ver. 4.03 software (GraphPad Software, La Jolla, CA). Data are presented as mean ± SD. The differences in all data were assessed by one-way analysis of variance (ANOVA). Differences were considered statistically significant at  $P < 0.05$ .

## **Results**

#### *Inhibitory effects of umbelliprenin on cell lines*

The  $IC_{50}$  of umbelliprenin on cancer cell lines of CT26 and L929 in 24, 48, and 72 h of incubation is shown in Table 1 & Figure 1. Results showed that inhibitory effects of umbelliprenin in concentrations of 25 and 50 µg/mL were significantly different between incubation times ( $P < 0.05$ ). The results showed that  $IC_{50}$  of L929 cells was three times greater than CT26 tumor cells.

#### *In-vivo effects of umbelliprenin*

##### *Body weight*

Results showed that body weight alteration between and within groups in time course of the study didn't change significantly both in tumor bearing and normal mice ( $P > 0.05$ ) (Figure 2).

**Table 1.** Mean IC<sub>50</sub> ± SD (95% CI) of umbelliprenin for CT26 and L929 cell lines.

Cell line	24 h	48 h	72 h
CT26	51.4 ± 2.9 (46-57.4)	53.2 ± 3.6 (46.6-60.8)	56.37 ± 2.5 (51.6-61.6)
L929	173.4 ± 2.9 (169-177.4)	134.2 ± 3.6 (140.6-128.8)	164.37 ± 2.5 (158.6-169.6)

### Tumor volume

From 14<sup>th</sup> day the tumor mass was measurable. Although there was no significant difference between group receiving umbelliprenin and control group and liquid paraffin group up to day 22; however, the mean TV/BW in umbelliprenin group in days 24, 26, 30, and 32 were significantly decreased compared to control and liquid paraffin group. There was no significant difference for mean TV/BW between any liquid paraffin and control groups in any day ( $P > 0.05$ ) (Figures 3 & 4)

### Serum IFN- $\gamma$ and IL-4

Serum concentration of IFN- $\gamma$ , showed significant increase in umbelliprenin group compared to control group and liquid paraffin group in both normal and tumor bearing mice. On the other hand, serum concentrations of IL-4 showed significant decrease in both tumor and normal mice on umbelliprenin compared to control group and liquid paraffin group


(Figure 5).

### Immunohistochemistry


Proportion of active nuclei indicated by Ki-67 expression, was decreased significantly in umbelliprenin group (A) compared to liquid paraffin (B) and normal saline (C) group ( $P < 0.001$ ). Expression of CD31, VEGF, MMP2, and MMP9 markers in umbelliprenin group (A) showed significant decrease compared to liquid paraffin (B) and normal saline (C) group ( $P < 0.05$ ). Also, the expression rate of E-cadherin in umbelliprenin (A) group was significantly increased compared to normal saline (C) and liquid paraffin (B) groups ( $P < 0.001$ ) (Figures 6 & 7).

### Histopathology results

The average of pCR and percentage of tumor cells destroyed in umbelliprenin group was significantly higher compared to normal saline (C) and liquid paraffin group (B) ( $P < 0.001$ ).



**Figure 2.** Mice body weights in study groups: Umbelliprenin (group A & D), liquid paraffin (group B & E) and saline (group C & F). Each point represents mean of 6 mice body weight ± S.E.M.



**Figure 3.** Tumor volume/Body weight ratio (TV/BW) in tumor bearing mice. Each bar represents mean of 6 mice  $\pm$  S.E.M.

(Figure 8).

*Evaluation of metastasis to liver, lung and kidneys*

No signs of metastasis to kidneys observed in any tumor-bearing mice groups. There were no metastasis signs in liver, and lung in umbelliprenin group, but, three metastasis cases to liver and four metastasis cases to lung were observed in liquid paraffin group, and two metastasis cases to liver and 6 cases to lung were observed in normal saline group.

*Effects of umbelliprenin on the liver, lung and kidneys in normal mice*


Umbelliprenin in normal (non-tumor) mice

had some effects (Table 2).


**Discussion**

Colorectal cancer after stomach and esophagus cancer, is the most prevalent gastrointestinal cancer in Iran (13). Results of the present study showed that umbelliprenin has concentration-dependent toxic effects against CT26 cancer cell line. The evaluation of  $IC_{50}$  in the studied cell lines showed that the toxic effects of umbelliprenin on L929 cell line was more than CT26 cell line in all three incubation times.

Until now, the cytotoxic effects of umbelliprenin on different cancer cell lines were




**Figure 4.** photographs of tumors extracted from the 6 mice at the end of study.




**Figure 5.** Mean of Serum concentration of IFN- $\gamma$  and IL-4 in tumor-bearing groups (Umbelliprenin (A), liquid paraffin (B), and normal saline (C)) and normal mice (Umbelliprenin (D), liquid paraffin (E), and normal saline (F)).

evaluated in different studies. The results of Khaghanzadeh *et al.* showed that umbelliprenin has inhibitory activity against adenocarcinoma and lung cancer cells at low concentrations, but has no toxic activity against PBMCs (11). Barthomeuf *et al.* found that cytotoxic activity

of umbelliprenin leads to inhibition of cancer cell lines of melanoma, lungs, prostate, ovaries, breasts, and colon. They find that high toxicity of umbelliprenin on M4Beu cells is mediated by inhibition of G1 in cell cycle and apoptosis induction via caspase cascade, and also low



**Figure 6.** Immunohistochemical results of Ki-67, CD31, VEGF, MMP2, MMP9 and E-cadherin in tumor groups treated with umbelliprenin (A), liquid paraffin (B) or normal saline (C).



**Figure 7.** Photography of Immunohistochemical staining of Ki-67, CD31, VEGF, MMP2, MMP9 and E-cadherin in tumor-bearing mice.

cytotoxicity on primary fibroblasts (9). In Rashidi *et al.* study, it has been determined that umbelliprenin has the potential of inhibitory activity against tumor cells (14). Furthermore, it was found that the inhibitory activity of umbelliprenin is significantly higher against breast cancer cells (4T1 and MCF-7) (14). This study also showed that umbelliprenin at cytotoxic concentrations could not inhibit normal cells (14). Gholami *et al.* demonstrated that umbelliprenin, by activation of caspase 8 and 9, activates internal and external apoptosis

pathways respectively in Jurkat T-CLL. Moreover, they showed that umbelliprenin promotes apoptosis process by inhibition of Bcl-2 (15).

In the present study, the mean TV/BW in umbelliprenin group was significantly decreased in days 24, 26, 30, and 32 compared to normal saline and liquid paraffin groups. Generally, our findings showed that umbelliprenin can be effective in reduction of tumor size. These findings were consistent with Iranshahi *et al.* (9) and also Khaghanzadeh *et al.* studies (6, 11) Probably by the induction of apoptosis mechanisms noted above.

Angiogenesis in various tumors such as colorectal cancer is mediated by different molecules such as IL-1 $\beta$ , bFGF, VEGF, MMPs, and TNF $\alpha$ . Oncologic alterations of tumor cells can play role via angiogenic factors in induction and development of angiogenesis (16, 17). In the present study, IHC method was used to evaluate angiogenesis and metastasis in tumor tissues by MMP2, MMP9, VEGF, and CD31 markers assay. The results of this study showed significant decrease in expression of VEGF, MMP2, MMP9, and CD31 factors in tumor-bearing mice under treatment with umbelliprenin compared to normal saline group. Furthermore, in our study, there were no signs of metastasis to liver, lungs, and kidneys in the umbelliprenin group. The results of our study indicates the important role of umbelliprenin in inhibition of metastasis of colorectal cancer cells especially to liver and lung. Studies have shown that inhibition or reduction of VEGF, MMP2, MMP9, and CD31 activity leads to reduction of angiogenesis, invasion, and cancer cell metastasis (18-22). It seems that umbelliprenin by decreasing expression of these factors leads to less metastasis, although the mechanism details need to be understood.

On the other hand, the expression of E-cadherin marker in umbelliprenin group was significantly increased compared to normal saline and liquid paraffin groups. E-cadherin is a membrane protein with essential role in cell-cell connection, and its decrease leads to unclenching of cancer cells and increases the possibility of metastasis (23, 24). It seems that the increasing of E-cadherin expression under

**Table 2.** Histopathologic status of liver, lung and kidneys in normal mice.


Groups	Tissues		
	Liver (No. of mice)	Lung (No. of mice)	Kidney (No. of mice)
Umbelliprenin (Group D)	Normal (5) Mild necrosis (1)	Normal (3) necrosis (1) Edema (2)	Normal (5) Edema (1)
Liquid paraffin (Group E)	Normal (2) Mild necrosis(2) Edema (1) Mild necrosis + Edema (1)	Normal (3) Edema (3)	Normal (4) Edema (1) Infiltrative cells + Edema (1)
Normal saline (Group F)	Normal (6)	Normal (4) Edema (1) Infiltrative cells (1)	Normal (6)

the influence of umbelliprenin leads to stability of cell connections and probably inhibition of expression of metastatic factors induced by beta-cadherin.

Also, the results showed that expression of Ki-67 marker in tumor-bearing mice treated with umbelliprenin was significantly decreased. The decrease of Ki-67 via umbelliprenin can lead to reduction and inhibition of cell deviation which

is one of the most important characteristics of cancer cells, and this process also can be effective in reduction of cancer cells proliferation (25).

Furthermore, in the present study, we evaluated the necrosis rate and presence of malignant cells (mitosis and polymorphism) by using H&E staining and application of pathologic complete response system (pCR). The average of pCR and percentage of destroyed tumor cells



**Figure 8.** H&E staining of tumor groups. pCR scanning based on H&E stained samples of tumor-bearing mice showed significant tumor destruction by umbelliprenin (A) compared to liquid paraffin (B) and normal saline (C) groups.



in umbelliprenin group were significantly more than normal saline and liquid paraffin groups.

In the present study, umbelliprenin significantly increased IFN- $\gamma$  and decreased IL-4. Increasing of IFN- $\gamma$  leads to activation of immune system against cancer cells and therefore induction of apoptosis in them (26). Studies have shown that IL-4 can lead to regulation of anti-tumor immune responses. The reduction of IL-4 levels in mice treated with umbelliprenin can help the anti-tumor activity of umbelliprenin. These results are consistent with findings of other researchers, as with Khaghanzadeh *et al.* (11). However, in our study, umbelliprenin increased levels of IFN- $\gamma$  and decreased IL-4 both in tumor and non-tumor animals. These changes may be related to the direct effects of umbelliprenin on immune system, and needs more investigation.

### Conclusion

Our results showed selective cytotoxicity of umbelliprenin on CT26 cells relative to L929 ones. Furthermore, umbelliprenin treatment in animal model of colorectal cancer showed reduction of tumor size, angiogenesis (showed by VEGF, MMP2, MMP9, and CD31 reduction and E-cadherin increment), proliferation (showed by KI-67 marker), and metastasis (showed by MMP2, MMP9 reduction and also no signs of liver, lung, and kidney metastasis). Umbelliprenin also potentiates immune response by IFN- $\gamma$  increment and IL-4 decrease. So it is a good candidate for further investigations.

### Acknowledgment

This study is a part of Dr. Mohamad Naderi Alizadeh PhD thesis, and also supported by a grant No M147 from Research Department of School of Medicine, Shahid Beheshti University of Medical Sciences.

### References

- (1) Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A and Yamauchi M. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N. Engl. J. Med.* (2013) 369: 1095-105.
- (2) Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Pourhoseingholi A, Barzegar F and Pourhoseingholi MA. Increased trend of breast cancer mortality in Iran. *Asian Pac. J. Cancer Prev.* (2012) 13: 367-70.
- (3) Shakeri A, Iranshahi M and Iranshahi M. Biological properties and molecular targets of umbelliprenin—a mini-review. *J. Asian Nat. Prod. Res.* (2014) 16: 884-9.
- (4) Nazari ZE and Iranshahi M. Biologically active sesquiterpene coumarins from *Ferula* species. *Phytother. Res.* (2011) 25: 315-23.
- (5) Venugopala KN, Rashmi V and Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. *BioMed. Res. Inter.* (2013) 2013.
- (6) Iranshahi M, Askari M, Sahebkar A and Adjipavlou-Litina D. Evaluation of antioxidant, anti-inflammatory and lipoxygenase inhibitory activities of the prenylated coumarin umbelliprenin. *DARU J. Pharm. Sci.* (2015) 17: 99-103.
- (7) Patel Rajesh M and Patel Natvar J. *In-vitro* antioxidant activity of coumarin compounds by DPPH, Super oxide and nitric oxide free radical scavenging methods. *J. Adv. Pharm. Education Res.* (2011) 1: 52-68.
- (8) Mousavi SH, Davari A-S, Iranshahi M, Sabouri-Rad S and Najaran ZT. Comparative analysis of the cytotoxic effect of 7-prenyloxycoumarin compounds and herniarin on MCF-7 cell line. *Avicenna j. phytomed.* (2015) 5: 520.
- (9) Barthomeuf C, Lim S, Iranshahi M and Chollet P. Umbelliprenin from *Ferula szowitsiana* inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis. *Phytomedicine* (2008) 15: 103-11.
- (10) Askari M, Sahebkar A and Iranshahi M. Synthesis and purification of 7-prenyloxycoumarins and herniarin as bioactive natural coumarins. *Iran. J. Basic Med. Sci.* (2009) 12: 63-9.
- (11) Khaghanzadeh N, Samiei A, Ramezani M, Mojtahedi Z, Hosseinzadeh M and Ghaderi A. Umbelliprenin induced production of IFN- $\gamma$  and TNF- $\alpha$ , and reduced IL-10, IL-4, Foxp3 and TGF- $\beta$  in a mouse model of lung cancer. *Immunopharmacol. Immunotoxicol.* (2014) 36: 25-32.
- (12) Jensen MM, Jørgensen JT, Binderup T and Kjær A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18 F-FDG-microPET or external caliper. *BMC Med. imaging* (2008) 8: 16.
- (13) Zarea K, Beiranvand S, Ghanbari S and Tuveesson H. Incidence of Gastrointestinal Cancers in Iran: A Systematic Review. *Jundishapur J. Chronic Dis. Care* (2016).
- (14) Rashidi M, Ziai SA, Zanjani TM, Khalilnezhad A and Amani D. Umbelliprenin is Potentially Toxic against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful against Bone Marrow-Derived Stem Cells, and Non-Toxic against Peripheral Blood Mononuclear Cells. *Iran. Red Crescent Med. J.* (2016) 18: e35167

- (15) Gholami O, Jeddi-Tehrani M, Iranshahi M, Zarnani AH and Ziai SA. Umbelliprenin from *Ferula szowitsiana* Activates both Intrinsic and Extrinsic Pathways of Apoptosis in Jurkat T-CLL cell line. *Iran. J. Pharma. Res.* (2013) 12: 371-76.
- (16) Rivera L, Pandika M and Bergers G. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. *Tumor Microenvironment and Cellular Stress*: Springer; (2014). p. 83-99.
- (17) Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R and Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. *Cytokine Growth Factor Rev.* (2005) 16: 159-78.
- (18) English BC, Price DK and Figg WD. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy. *Cancer Biol. Ther.* (2009) 8: 1212-13.
- (19) Zhang J, Lu A, Beech D, Jiang B and Lu Y. Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis. *Cancer Ther.* (2007) 5: 273.
- (20) Mendes O, Kim H-T and Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. *Clin. Exp. Metastasis* (2005) 22: 237-46.
- (21) Mehner C, Hockla A, Miller E, Ran S, Radisky DC and Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. *Oncotarget* (2014) 5: 2736-49.
- (22) Shahverdi A, Saadat F, Khorramizadeh M, Iranshahi M and Khoshayand M. Two matrix metalloproteinases inhibitors from *Ferula persica* var. *persica*. *Phytomedicine* (2006) 13: 712-17.
- (23) Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Res.* (2008) 68: 3645-54.
- (24) Jeanes A, Gottardi C and Yap A. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? *Oncogene* (2008) 27: 6920-29.
- (25) Li LT, Jiang G, Chen Q and Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (Review). *Mol. Med. Rep.* (2015) 11: 1566-72.
- (26) Alshaker HA and Matalka KZ. IFN- $\gamma$ , IL-17 and TGF- $\beta$  involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. *Cancer Cell Int.* (2011) 11: 33.

---

This article is available online at <http://www.ijpr.ir>